Abstracts tagged "immunology"

Abstract Number: 0195 • ACR Convergence 2020
Epidemiology and Characteristics of Incident Rheumatoid Arthritis in Persons with and Without HIV
Jennifer Hanberg¹, Kathleen Akgun², Liana Fraenkel³, Evelyn Hsieh² and Amy Justice⁴, ¹Yale University School of Medicine; West Haven VA, Boston, MA, ²Yale University School of Medicine; West Haven VA, New Haven, CT, ³Yale School of Medicine; West Haven VA; Berkshire Medical Center, Lenox, MA, ⁴Yale University School of Medicine; Yale School of Public Health; West Haven VA, West Haven, CT
Background/Purpose: Rheumatoid arthritis (RA) is the most common chronic inflammatory arthritis, affecting 1-2% of the population. Estimates of the incidence of RA in patients with…
Abstract Number: 0753 • ACR Convergence 2020
Synovial Tissue Histopathology Findings in Early RA. Is It Useful? Analysis of the Belgian CAP48 Cohort
Stéphanie de Montjoye¹, Tatiana Sokolova¹, Emilie Sapart¹, Bernard Lauwerys², Stéphanie Dierckx³, Christine Galant⁴, Laurent Meric de Bellefon¹, Adrien Nzeusseu Toukap⁵, Clément Triaille⁶ and Patrick Durez⁷, ¹Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ³Rheumatology, CHU Mont-Godinne, Mont Godinne, Belgium, ⁴3Pathology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, ⁵1Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium, ⁶Rheumatology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, ⁷Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Background/Purpose: Rheumatoid arthritis is a heterogeneous disease with different clinical presentation and prognostic factors including the immune process in the synovium. The development of ultrasound-guided…
Abstract Number: 1409 • ACR Convergence 2020
Lack of Conventional Acinar Cells in the Salivary Gland Following Anti PD-L1 and anti-PD-1 Immune Checkpoint Inhibitor Therapy
Sarah Pringle¹, Bert van der Vegt¹, Xiaoyan Wang¹, Nico van Bakelen¹, Arjan Vissink¹, Frans Kroese² and Hendrika Bootsma², ¹UMCG, Groningen, ²University Medical Centre Groningen, Groningen, Netherlands
Background/Purpose: Salivary glands (SGs) can be damaged by immune checkpoint inhibitor (ICI) therapy. In patients with ICI-induced SG dysfunction, 60% progress to fulfill the ACR-EULAR…
Abstract Number: 1750 • ACR Convergence 2020
Longitudinal Change in the Central Nervous System Pain Response After Treatment with Certolizumab or Placebo. a Post-hoc Analysis from the Pre-CEPRA Trial
Juergen Rech¹, Hannah Schenker², Koray Tascilar¹, Melanie Hagen², Larissa Valor Mendez², Verena Schoenau³, Marina Sergeeva⁴, Jutta Prade⁴, Mageshvar Sulvakumar⁵, Laura Konert⁶, Arnd Kleyer¹, David Simon¹, Sandra Strobelt⁴, Frank Behrens⁷, Christoph Baerwald⁸, Stephanie Finzel⁹, Reinhard Voll¹⁰, Axel Hueber¹¹, Eugen Feist¹², Julie Roesch¹³, José A. P. da Silva¹⁴, Arnd Doerfler¹³, Nemanja Damjanov¹⁵, Andreas Hess¹⁶ and Georg Schett¹⁷, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, ³Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, ⁴Institute for Experimental Pharmacology, Erlangen, Germany, ⁵Insitute for Experimental Pharmacology, FAU Erlangen-Nuremberg, Erlangen, Germany, ⁶Institute for Experimental Pharmacology, FAU Erlangen-Nürnberg, Erlangen, ⁷CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ⁸Uniklinik Leipzig, Medizinische Klinik III - Bereich Rheumatologie, Leipzig, Germany, ⁹Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, ¹⁰Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freibrug, ¹¹Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, ¹²Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, ¹³Abteilung für Neuroradiologie, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, ¹⁴9.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, ¹⁵Belgrade University School of Medicine, Belgrade, Serbia, ¹⁶Institute for Experimental Pharmacology, Erlangen, ¹⁷Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Biologicals - bring a hope of recovery or amelioration to people suffering from RA, but only half of the patients respond to such treatment.…
Abstract Number: 0207 • ACR Convergence 2020
Upadacitinib Monotherapy in Methotrexate-naïve Patients with Rheumatoid Arthritis: Results at 72 Weeks
Ronald van Vollenhoven¹, Tsutomu Takeuchi², Maureen Rischmueller³, Ricardo Blanco⁴, Ricardo Xavier⁵, Mark Howard⁶, Alan Friedman⁶, Yanna Song⁷ and Vibeke Strand⁸, ¹Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ³The Queen Elizabeth Hospital and Univ of Adelaide, St Peters, South Australia, Australia, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁵Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Rio Grande do Sul, Brazil, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., North Chicago,, IL, ⁸Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, demonstrated significant improvements in signs, symptoms, and structural inhibition as monotherapy vs methotrexate (MTX) in a randomized, controlled…
Abstract Number: 0770 • ACR Convergence 2020
Effect of Citrullination on the Processing and Presentation of Rheumatoid Arthritis Autoantigens
Ashley Curran¹, Jonathan Crawford¹ and Erika Darrah¹, ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Citrullinated proteins are hallmark targets of the autoimmune response in rheumatoid arthritis (RA), but the mechanism by which immune tolerance is broken to these self-proteins…
Abstract Number: 1413 • ACR Convergence 2020
An Imbalance Between Regulatory and Inflammatory T Cell Subsets Distinguishes Systemic Autoimmune Rheumatic Disease Patients from Asymptomatic ANA+ Individuals
Emma Vanlieshout¹, Rashi Gupta¹, Dennisse Bonilla², Michael Kim³, Sindhu Johnson², Earl D. Silverman⁴, Linda Hiraki⁵, Zareen Ahmad⁶, Zahi Touma⁷, Arthur Bookman² and Joan Wither², ¹Krembil Research Institute, Toronto, ON, Canada, ²University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Krembil Research Insitute, Toronto, ON, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: The anti-nuclear antibody (ANA)-associated systemic autoimmune rheumatic diseases (SARDs) are characterized by a prolonged preclinical phase in which ANAs are produced in the absence…
Abstract Number: 1757 • ACR Convergence 2020
High-Intensity Interval Training Increases Rheumatoid Arthritis Cardiorespiratory Fitness in Association with Improvements in CD4+ T Cell and Skeletal Muscle Mitochondrial Metabolism
Brian Andonian¹, David Bartlett¹, Alec Koss¹, Deborah Muoio¹, Timothy Koves¹, Eugene St Clair¹, Elizabeth Hauser¹, William Kraus¹ and Kim Huffman¹, ¹Duke University, Durham, NC
Background/Purpose: Persons with rheumatoid arthritis (RA) have poor cardiorespiratory fitness and are at increased risk for cardiometabolic co-morbidities. Endurance exercise training improves cardiorespiratory fitness in…
Abstract Number: 0234 • ACR Convergence 2020
Characterization of Serious Infections with Upadacitinib in Patients with Rheumatoid Arthritis
Kevin Winthrop¹, Leonard Calabrese², Filip Van den Bosch³, Kunihiro Yamaoka⁴, Carlo Selmi⁵, Yanna Song⁶, Barbara Hendrickson⁷, Ivan Lagunes-Galindo⁸ and Iain McInnes⁹, ¹Oregon Health & Science University, Portland, OR, ²Cleveland Clinic, Cleveland, OH, ³Ghent University Hospital, Ghent, Belgium, ⁴Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan, ⁵Humanitas Research Hospital and Humanitas University, MIlan, Italy, ⁶AbbVie Inc., North Chicago,, IL, ⁷AbbVie, Inc, North Chicago, IL, ⁸AbbVie Inc., North Chicago, IL, ⁹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Upadacitinib (UPA) is a selective and reversible Janus kinase (JAK) inhibitor with an approved dose of 15 mg once daily (QD) for the treatment…
Abstract Number: 0772 • ACR Convergence 2020
Modification of THP-1 Cells with Malondialdehyde-Acetaldehyde Increases Cellular Calcium Load Rendering Cells Susceptible to Citrullination of Self-Proteins
Nozima Aripova¹, Michael Duryee¹, Xiarepati Tieliwaerdi¹, Xiaoting Jiang¹, Lynell Klassen², James O'Dell¹, Bryant England¹, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Univerisity of Nebraska Medical Center, Omaha, NE
Background/Purpose: The post translational modification of self-proteins with malondialdehyde-acetaldehyde (MAA) has been shown to alter protein function and antibodies to MAA are increased in both…
Abstract Number: 1440 • ACR Convergence 2020
The Myeloperoxidase (MPO) Anti-Neutrophilic Cytoplasmic Antibody (ANCA) Binding Epitope, MPO447-459 Induces CD4 T-cell Proliferation in Patients with MPO-ANCA-associated Vasculitis
Matthew Terrill¹, Hendrik Nel², Yassmin Musthaffa³, Wong Richard⁴, Ross Francis⁵, David Johnson⁵, Greg Keir⁶, David Gillis⁷ and Ranjeny Thomas⁸, ¹University of Queensland Diamantina Institute and Princess Alexandra Hospital, Rheumatology Department, Brisbane- Australia, Moffat beach, Queensland, Australia, ²University of Queensland Diamantina Institute, Brisbane, Queensland, Australia, ³University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Immunology Department, Princess Alexandra Hospital, Brisbane- Australia, Brisbane, Australia, ⁵Renal Department, Princess Alexandra Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁶Respiratory Department, Princess Alexandra Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁷Immunopathology Department, Royal Women’s and Children’s Hospital, Brisbane- Australia., Brisbane, Queensland, Australia, ⁸University of Queensland Diamantina Institute and Rheumatology Department, Princess Alexandra Hospital, Brisbane – Australia., Brisbane, Australia
Background/Purpose: In Myeloperoxidase (MPO) Anti Neutrophilic Cytoplasmic Antibody (ANCA)-Associated Vasculitis (MPO-AAV), murine and human studies suggest that the MPO435-465 region, which includes ANCA-binding MPO447-459, the…
Abstract Number: 1843 • ACR Convergence 2020
Integrated Efficacy of the AURORA 1 and AURA-LV Trials Confirms Voclosporin Rapid Proteinurea Reduction in the Presence of Low-Dose Steroids
Ellen M Ginzler¹, Joshua Kaplan², Laura Lisk³, Ray Federico⁴, Neil Solomons⁵ and Robert Huizinga⁵, ¹SUNY Downstate Health Sciences University, Brooklyn, ²Rutgers University, New Brunswick, NJ, ³Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ⁴Aurinia Pharmaceuticals, Inc., Victoria, Canada, ⁵Aurinia Pharmaceuticals, Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor (CNI) with a favorable metabolic profile and a consistent predictable dose response potentially eliminating the need for…
Abstract Number: 0237 • ACR Convergence 2020
Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis
Stanley Cohen¹, Ronald F Van Vollenhoven², Jeffrey Curtis³, Leonard Calabrese⁴, Cristiano AF Zerbini⁵, Yoshiya Tanaka⁶, Louis Bessette⁷, Casey Schlacher⁸, Tim Shaw⁹, John Liu⁹, Jeffrey Enejosa⁹, Yanna Song¹⁰ and Gerd Burmester¹¹, ¹Metroplex Clinical Research Center, Dallas, TX, ²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Cleveland Clinic, Cleveland, OH, ⁵Centro Paulista de Investigacao Clinica (CEPIC), Sao Paulo, Brazil, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Laval University, Quebec, Canada, ⁸AbbVie Inc., Lake Forest, IL, ⁹AbbVie Inc., North Chicago, IL, ¹⁰AbbVie Inc., North Chicago,, IL, ¹¹Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: The safety and efficacy of upadacitinib (UPA), an oral JAK inhibitor, was evaluated in the phase 3 SELECT clinical program, which included 5 randomized,…
Abstract Number: 0773 • ACR Convergence 2020
The Anti-carbamylated Fibrinogen Response in Rheumatoid Arthritis Targets a Specific Epitope on the γ-chain and Is Associated with a More Active Disease
Pauline Brevet¹, Manuel Freret¹, Pascal Rottenberg², Clément Guillou³, Thierry Lequerre⁴, Pascal Cosette⁵, Olivier Boyer² and Olivier Vittecoq⁶, ¹Inserm U1234 and Rouen University , IRIB, Rouen, France ; Rouen University Hospital, Rheumatology Department, Rouen, France, Rouen, Haute-Normandie, France, ²Inserm U1234 and Rouen University , IRIB, Rouen, France ; Rouen University Hospital, Rheumatology Department, Rouen, France, Rouen, France, ³CNRS 6270, PISSARO, IRIB, Rouen, France ; Centre hospitalo-universitaire de Rouen, Immunology Laboratory, Rouen, France, Rouen, Haute-Normandie, France, ⁴Rheumatology, University Teaching Hospital, Rouen, France, ⁵CNRS 6270, PISSARO, IRIB, Rouen, France ; Centre hospitalo-universitaire de Rouen, Immunology Laboratory, Rouen, France, Rouen, France, ⁶University Hospital of Rouen, Rouen, France
Background/Purpose: Anti-carbamylated protein autoantibodies (anti-CarP Abs) of IgG and/or IgA isotype have potential diagnostic and prognostic value Carbamylated Fetal Calf Serum (FCS) is the substrate…
Abstract Number: 1506 • ACR Convergence 2020
Correction of Sjögren’s Syndrome Fluid Secretion Deficits in Salivary Gland Acinar Cells by Aquaporin-1 Gene Transfer
Paola Perez¹, Blake Warner², Sandra Wainer¹, Youngmi Ji¹, Thomas Pranzatelli¹ and Jay Chiorini¹, ¹Nidcr, National Institute of Health, Bethesda, MD, ²National Institute of Dental and Craniofacial Research, Bethesda
Background/Purpose: The hallmark clinical complaints in Sjögren’s syndrome (SS) are dry mouth and dry eyes related to salivary and lacrimal glands dysfunction. Reduced salivation reflects…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].